Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

"Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

U.S. and China Asthma and COPD Drugs Market: Overview

Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the WHO predicts that COPD will become the third most common cause of death globally by 2030. However, these statistics have already materialized in the U.S. and China, where COPD is currently said to be the third leading cause of mortality.

Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=893048

U.S. and China Asthma and COPD Drugs Market: Scope and Methodology

This report on the asthma and COPD drugs market in the U.S. and China analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year.

U.S. and China Asthma and COPD Drugs Market: Segmentation

Based on drug class, the asthma and COPD drugs market in the U.S and China has been segmented into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. The bronchodilator class has been further segmented into short acting beta-2 agonists, long acting beta-2 agonists, and anti-cholinergic agents. The anti-inflammatory drug class has been further segmented into oral and inhaled corticosteroids, anti-leukotrienes, phosphodiesterase type 4 inhibitors, and others. The others segment includes mast cell stabilizers and other anti-inflammatory agents used in asthma and COPD control.

U.S. and China Asthma and COPD Drugs Market: Competitive Landscape

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the asthma and COPD drugs market in the U.S. and China. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

The U.S. and China asthma and COPD drugs market has been segmented as follows:

U.S. and China Asthma and COPD Drugs Market, by Drug Class

Bronchodilators 

• Short Acting Beta-2 Agonists
• Long Acting Beta-2 Agonists
• Anti-cholinergic Agents 

Anti-inflammatory Drugs 

• Oral and Inhaled Corticosteroids
• Anti-leukotrienes
• Phosphodiesterase Type-4 Inhibitors
• Others 

Monoclonal Antibodies
Combination Drugs

U.S. and China Asthma and COPD Drugs Market, by Indication

• Asthma
• COPD